Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus relatlimab in advanced or metastatic soft-tissue sarcoma
2019-002332-81Phase 2Active
- Sponsor
- Institut Bergonié
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and relatlimab in soft tissue sarcoma (STS) (2 arms), sponsored by Institut Bergonié. Primary endpoint: 6-month progression-free rate. Started Sep 2019; status: active.
02
Drugs
nivolumabrelatlimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2019-002332-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002332-81.